Norvasc®
Amlodipine Besylate
Version 2025-04 · Last reviewed April 1, 2025 · Methodology
List Price
$30
With Insurance
$4
The Short Version
Evidence summary
Norvasc (Amlodipine Besylate) is a Calcium Channel Blocker (Dihydropyridine) prescribed for Hypertension and Chronic stable angina. FDA-approved in 1987.
Blood pressure begins to fall within 6-12 hours, but amlodipine has an unusually long half-life (30-50 hours). Full blood pressure effect takes 7-10 days.
The most commonly reported side effects are Peripheral edema (ankle swelling) (10-15%), Headache (7%), Fatigue (5%). Dose-dependent; most common at 10mg. Not heart failure — it is local vasodilation. Leg elevation helps.
Research funding is mixed — some independent, some manufacturer-funded.
What This Really Costs
Long-term cost projection based on current pricing
Monthly
$15
$4 w/ insurance
without insurance
Annual
$180
$48 w/ insurance
without insurance
10 Years
$1.8K
$480 w/ insurance
without insurance
30 Years
$5.4K
$1.4K w/ insurance
without insurance
Lifestyle alternative: $0/month in prescriptions. Weight loss — Approximately −1 mmHg systolic per kg lost; larger reductions with significant excess weight.
The average American retiree spends $165,000 on healthcare over their lifetime (Fidelity, 2024). Informed choices today compound over decades.
Quick Answers
Now what?
You've read the evidence. Here are your next steps.
Related Evidence
Explore related medications reviewed on EvidentMeds
How It Works
Amlodipine blocks L-type calcium channels in vascular smooth muscle cells. When calcium cannot enter the muscle cells, the blood vessel walls relax and widen — lowering blood pressure. It is highly selective for blood vessels (not heart muscle), which is why it does not slow heart rate the way some other calcium channel blockers do.
Why the side effects happen
The ankle swelling (edema) is caused by selective arteriolar dilation: the arteries widen but the veins do not, creating a pressure gradient that pushes fluid into tissues. This is NOT heart failure — it is a local vascular effect. Flushing and headache are also caused by vasodilation.
When Will I Feel It?
Blood pressure begins to fall within 6-12 hours, but amlodipine has an unusually long half-life (30-50 hours). Full blood pressure effect takes 7-10 days.
Modest blood pressure reduction begins. Amlodipine is absorbed slowly and has a very gradual onset compared to other antihypertensives.
Steady-state blood pressure lowering achieved. This is when the full effect is visible and dose adjustments should be made.
Consistent blood pressure control. The long half-life means a missed dose has less impact than with shorter-acting drugs.
Adherence Note
Amlodipine's very long half-life (30-50 hours) is an advantage for adherence — missing a single dose causes less blood pressure rebound than with shorter-acting medications.
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Metabolic & Lifestyle Alternatives
Lifestyle Approaches for Blood Pressure
Weight loss, alcohol reduction, and eliminating ultra-processed foods appear to be among the most potent lifestyle levers for blood pressure — with effects comparable to first-line medications in some patients.
Important context: Evidence quality varies across these approaches. Some are well-studied with randomized controlled trial data; others are based on observational or smaller studies. These interventions are not guaranteed to replace medication for all patients. Discuss with your doctor whether any of these are appropriate for your clinical situation.
Weight loss
Most consistently evidenced intervention. Obesity drives hypertension through insulin resistance, leptin signaling, and sympathetic nervous system activation.
Approximately −1 mmHg systolic per kg lost; larger reductions with significant excess weight
DASH diet pattern
Rich in vegetables, fruits, whole grains, lean protein. High in potassium and magnesium, low in ultra-processed food. The BP-lowering effect may come more from removing processed food than from sodium restriction.
−8 to −14 mmHg systolic in hypertensive patients
Aerobic exercise
150 minutes/week of moderate activity. Reduces sympathetic tone, improves vascular function, and aids weight management.
−5 to −8 mmHg systolic average
Alcohol reduction
Alcohol raises blood pressure dose-dependently. Even moderate intake (2+ drinks/day) elevates systolic BP.
−4 to −7 mmHg systolic when reducing from moderate to low/none
Potassium-rich foods
Vegetables, legumes, and fruit promote sodium excretion. Many Americans are potassium-deficient.
−3 to −5 mmHg systolic with adequate potassium intake
Stress management
Chronic stress activates the sympathetic nervous system and raises cortisol. Meditation, deep breathing, and adequate sleep all contribute.
−2 to −4 mmHg systolic in studies of stress reduction techniques
Key Studies
How It Compares
Amlodipine is the most prescribed calcium channel blocker and the most prescribed antihypertensive in the world. Its long half-life, once-daily dosing, and safety in kidney disease make it widely preferred over other CCBs.
Strengths
- Most prescribed antihypertensive globally
- Long half-life = forgiving if a dose is missed
- Safe in kidney disease without dose adjustment
- No metabolic side effects (does not affect glucose, lipids, or potassium)
- Effective regardless of age, race, or dietary sodium intake
Weaknesses
- Ankle edema in 10-15% (dose-dependent)
- Gum overgrowth in some patients
- Cannot be used for rate control (unlike non-dihydropyridine CCBs like verapamil)
Clinically Preferred Alternatives
Global Prescribing & Pricing
Amlodipine is the most prescribed antihypertensive globally — used as first-line in virtually every country
United States
$30-60/mo
Most prescribed blood pressure medication overall
No lifestyle prerequisite required before prescribing
Usually covered
United Kingdom
~$1-4/mo
NICE first-line for hypertension in patients over 55 or Black patients of any age
Lifestyle advice mandated alongside prescribing
Fully covered by NHS
France
~$2-6/mo
Standard first-line per HAS guidelines
Lifestyle counseling reimbursed as part of care pathway
Covered by Sécurité Sociale
Germany
~$4-10/mo
First-line alongside lifestyle emphasis
Lifestyle intervention emphasized per DHL guidelines
Covered by GKV
Japan
~$8-20/mo
Most prescribed antihypertensive in Japan — preferred over ACE inhibitors due to lower cough rates
Strict BP targets; dietary programs promoted
Covered by JHIS
Amlodipine is the most prescribed blood pressure medication in the world — a genuine global consensus drug. The US pays $30-60/month for a medication that costs $1-4 in the UK. The molecule is identical.
Clinical Trials & Funding
Understanding who funds research helps contextualize results. Industry-funded trials are not automatically invalid — they undergo the same FDA review — but declared conflicts and sponsor effects are worth knowing. All linked trials can be verified on ClinicalTrials.gov.
Funding Sources
ALLHAT: Fully funded by the NIH National Heart, Lung, and Blood Institute — no pharmaceutical sponsorship. ASCOT-BPLA: Funded by Pfizer (manufacturer of Norvasc). CAMELOT: Funded by Pfizer. Two of three pivotal trials were industry-funded by the company that profited from the results.
Declared Conflicts of Interest
ASCOT-BPLA and CAMELOT investigators received research grants and consulting fees from Pfizer. ALLHAT was independently funded and remains the strongest evidence. The industry-funded trials compared amlodipine to older, less-favorable comparators.
Key Efficacy Results
ALLHAT: Equivalent to lisinopril and chlorthalidone for primary outcomes; ASCOT-BPLA: Superiority over atenolol for stroke prevention
Referenced Studies
Each study carries a Cochrane RoB-2 risk-of-bias badge — tap the badge for details.
Evidence & Transparency
Cochrane RoB-2 (Risk of Bias)
Badges reflect an editorial assessment using Cochrane's RoB-2 tool domains: randomization, intervention deviation, missing data, outcome measurement, and selective reporting. These are not certified Cochrane reviews. Learn more ↗
CMS Open Payments
Manufacturer payment disclosures are reported via the CMS Sunshine Act. Disclosure is legally required and does not imply bias or misconduct. Language uses "may," "suggests," or "appears" — never definitive clinical claims. CMS Open Payments ↗
Live Clinical Trials
Live from ClinicalTrials.gov · refreshed every 4 hours
Currently enrolling, active, and recently completed studies involving Amlodipine Besylate. Data is pulled directly from the U.S. National Library of Medicine.
Recent Research
Live from PubMed · peer-reviewed literature · refreshed every 4 hours
Most recently indexed clinical trials and systematic reviews mentioning Amlodipine Besylate in PubMed.
Source Documentation
Structured citations for referenced clinical trials
Each referenced trial is listed with its registry ID, funding source, and bias assessment. Use the copy button to generate a formatted citation.
| Trial | Registry ID | Cite |
|---|---|---|
| ALLHAT (NIH) | NCT00000542 | |
| ASCOT-BPLA (Pfizer) | PMID:16154016 | |
| CAMELOT (Pfizer) | NCT00049621 |
Bias ratings use Cochrane RoB-2 methodology. Editorial assessment — not a certified Cochrane review.
Our MethodologyMedical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Common Side Effects
While taking this medication, you may experience the following common side effects. We've included tips on how to manage them.
Peripheral edema (ankle swelling)
10-15%Dose-dependent; most common at 10mg. Not heart failure — it is local vasodilation. Leg elevation helps.
Dizziness
3-4%Usually in first week; rise slowly from sitting
Flushing / warmth
3%Common early in therapy; resolves as body adjusts
Fatigue
5%Often improves over first few weeks
Headache
7%Usually mild and self-limiting in first week
Palpitations
1-4%Reflex tachycardia from vasodilation — usually benign
Nausea
3%Take with food if needed
Gum overgrowth (gingival hyperplasia)
2-3%Good oral hygiene reduces risk; reversible if caught early
Serious Adverse Effects
- • Severe hypotension (especially with other antihypertensives)
- • Worsening angina or MI (rare, on initiation)
- • Hepatitis (rare)
- • Severe allergic reaction (angioedema — very rare)
Drug Interactions
Major Interactions (Avoid)
Moderate Interactions (Caution)
Food Interactions
When to Contact Your Doctor
This medication requires ongoing medical supervision. The following situations warrant a prompt conversation with your prescribing physician — do not wait for your next scheduled appointment.
Contact soon if you notice
- Severe hypotension (especially with other antihypertensives)
- Worsening angina or MI (rare, on initiation)
- Hepatitis (rare)
- Severe allergic reaction (angioedema — very rare)
- Blood pressure rising above 140/90 mmHg
Also discuss if you want to
- Review whether this medication is still appropriate for you
- Consider dosage adjustments based on response
- Explore lifestyle or non-drug alternatives
- Understand stopping or tapering options
- Plan monitoring labs and follow-up
In the US, call 911 or go to the nearest emergency room for severe symptoms. Poison Control: 1-800-222-1222.
Special Populations
Safety classifications for specific groups — discuss with your provider before use.
Category C. Animal data suggest risk. Nifedipine is the preferred CCB in pregnancy.
Passes into breast milk in small amounts. Monitor infant for low blood pressure.
Estrogen loss leads to vascular stiffness and rising blood pressure. Amlodipine is often prescribed to menopausal women because it works well regardless of age. Ask whether hormonal factors should be evaluated alongside blood pressure treatment.
Approved for hypertension in children 6 and older. Start at 2.5mg.
Start at 2.5mg. Greater sensitivity to hypotension. Edema risk increases with age.
Not renally cleared. Safe in kidney disease without dose changes.
FDA Adverse Event Reports
Patient-filed reports from the FDA FAERS database · refreshed daily
Community Reports
User-reported experiences — anonymous & anecdotal
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Stopping This Medication Safely
Abrupt discontinuation can cause rebound hypertension and worsening angina. Blood pressure may rise sharply within days of stopping.
What Published Research Shows About Stopping This Medication
This summarizes what published research documents — it is not personal medical advice. Any changes to your medication require discussion with your prescribing physician.
- ·Research supports gradual dose reduction rather than abrupt cessation — particularly in patients with coronary artery disease
- ·Published tapering approaches describe reducing from 10mg → 5mg → 2.5mg every 1-2 weeks
- ·Home blood pressure monitoring twice daily is recommended throughout the tapering process
- ·Building a whole-food dietary foundation before tapering (DASH pattern, exercise, weight management) improves success rates
Warning Symptoms — Contact Your Doctor If You Experience:
- Blood pressure rising above 140/90 mmHg
- Chest pain or pressure
- Severe headache
- Ankle swelling returning (may indicate need to resume)
Never change or stop a medication without consulting your prescribing physician.
Questions for Your Doctor
Questions to Ask
- 1.Can lifestyle changes lower my blood pressure enough to avoid medication?
- 2.Is amlodipine the best first-line choice for my age and background?
- 3.What should I do about the ankle swelling — is it dangerous?
- 4.Could I try a lower dose first?
Lab Tests to Request
- Blood pressure log (home monitoring)
- Kidney function (creatinine/BUN)
- Electrolytes (potassium, sodium)
- Liver function (if symptoms develop)
Medical Disclaimer
The information on this page is compiled from publicly available clinical trial data, FDA prescribing information, and peer-reviewed literature. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Individual responses to medications vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.
Frequently Asked Questions About Norvasc®
- What is Norvasc® used for?
- Norvasc® (Amlodipine Besylate) is a Calcium Channel Blocker (Dihydropyridine) manufactured by Generic (originally Pfizer). FDA-approved indications include: Hypertension; Chronic stable angina; Vasospastic (Prinzmetal) angina; Coronary artery disease.
- What are the common side effects of Norvasc®?
- Common side effects of Norvasc® include: Peripheral edema (ankle swelling) (10-15%); Dizziness (3-4%); Flushing / warmth (3%); Fatigue (5%); Headache (7%).
- How much does Norvasc® cost?
- Norvasc® list price is approximately $30. With insurance it typically costs $4; without insurance approximately $10-20.
- Who funded the clinical trials for Norvasc®?
- ALLHAT: Fully funded by the NIH National Heart, Lung, and Blood Institute — no pharmaceutical sponsorship. ASCOT-BPLA: Funded by Pfizer (manufacturer of Norvasc). CAMELOT: Funded by Pfizer. Two of three pivotal trials were industry-funded by the company that profited from the results.
- How strong is the clinical evidence for Norvasc®?
- Key studies: ALLHAT, ASCOT-BPLA, CAMELOT. ALLHAT: Equivalent to lisinopril and chlorthalidone for primary outcomes; ASCOT-BPLA: Superiority over atenolol for stroke prevention Potential conflicts of interest: ASCOT-BPLA and CAMELOT investigators received research grants and consulting fees from Pfizer. ALLHAT was independently funded and remains the strongest evidence. The industry-funded trials compared a.
- Are there non-drug alternatives to Norvasc®?
- Weight loss, alcohol reduction, and eliminating ultra-processed foods appear to be among the most potent lifestyle levers for blood pressure — with effects comparable to first-line medications in some patients. See the Alternatives tab for full details.
Get notified when we update Norvasc®
We'll email you when new evidence, safety updates, or alternatives are added.
No spam. Unsubscribe anytime.